Abstract
High-dose therapy followed by autologous stem cell transplantation (ASCT) is considered the standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (MM). With new treatment combinations offering the advantage of improved clinical outcomes of MM patients, the utilization of ASCT is again being addressed in the evolving treatment landscape. In this article, we review the role of frontline ASCT in the management of patients with MM.
| Original language | English |
|---|---|
| Pages (from-to) | 190-195 |
| Number of pages | 6 |
| Journal | Cancer Journal (United States) |
| Volume | 27 |
| Issue number | 3 |
| DOIs | |
| State | Published - 2021 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
ASJC Scopus subject areas
- Oncology
- Cancer Research
Keywords
- Autologous stem cell transplantation
- immunomodulator agents
- monoclonal antibodies
- multiple myeloma
- proteasome inhibitors
- upfront therapy
Fingerprint
Dive into the research topics of 'From VAD to VRD: Is Transplant Still Needed in the Upfront Setting of Myeloma?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver